Drugs in MeSH Category Antithyroid Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Macleods Pharms Ltd	METHIMAZOLE	methimazole	TABLET;ORAL	209827-002	May 24, 2023	AB	RX	No	No
Mylan	METHIMAZOLE	methimazole	TABLET;ORAL	040350-003	Jun 7, 2001		DISCN	No	No
Ph Health	PROPYLTHIOURACIL	propylthiouracil	TABLET;ORAL	006188-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Heritage Pharma	METHIMAZOLE	methimazole	TABLET;ORAL	040734-002	Dec 14, 2007	AB	RX	No	No

Market Dynamics and Patent Landscape for Antithyroid Agents (NLM MeSH Class): What Patents Protect Methimazole and Propylthiouracil, When Do Exclusivities Expire, and What Generic/Biosimilar Risks Exist

Last updated: July 11, 2026

Executive summary
Antithyroid agents in MeSH Class terms are dominated commercially by generic methimazole and propylthiouracil (PTU), with limited, incremental patent estates and a long history of off-patent molecules. Market dynamics are shaped less by brand patent exclusivity and more by (1) FDA drug shortages and supply stability, (2) label-directed use and safety restrictions (especially PTU hepatotoxicity and pregnancy management), (3) pharmacy-level substitution and contracting, and (4) formulation-level IP where it exists. For new entrants, the principal IP and regulatory gating is whether they can design around legacy formulation and manufacturing patents, and whether they face Orange Book-listed brand exclusivity for any still-protected antithyroid product.

Because “Antithyroid Agents” is a broad MeSH umbrella, a complete patent landscape requires product-level identification (strength, dosage form, NDA/ANDA/BLA and Orange Book listings). With no specific active ingredient, product, or jurisdiction supplied, the only complete and accurate market-patent statement possible is that the dominant actives (methimazole and PTU) are overwhelmingly generic in the US and other major markets, so the active-ingredient patent layer is largely expired. Any remaining IP risk is concentrated in (a) product-specific formulation, (b) process/method-of-manufacture, and (c) any narrow remaining exclusivities tied to specific NDA approvals.

---

What patents protect methimazole and propylthiouracil in the US market for antithyroid agents?

Short answer: For methimazole and PTU, the core active-ingredient patent estate is largely expired in major markets; remaining protection, where it exists, is typically formulation or manufacturing related and is usually not broad enough to prevent generic substitution for standard oral tablets or capsules.

Which antithyroid active ingredients dominate MeSH Class “Antithyroid Agents”?

The MeSH umbrella broadly covers:

• Methimazole
• Propylthiouracil (PTU)

In routine US practice, these are the primary non-radioiodine antithyroid medicines used for hyperthyroidism and Graves’ disease management.

How strong is the patent estate for methimazole and PTU?

• Active ingredient layer: generally weak as a barrier to generic entry because these are long-established molecules with expired compound and composition coverage.
• Product layer: some risk can persist around:
  • controlled-release or alternative solid-state forms (less common in antithyroid standards)
  • manufacturing processes or specific excipient systems
  • labeling-linked exclusivity (rare for these actives because most approvals are historical)

What patent types matter for antithyroid generics?

When still present, patent coverage in antithyroid products tends to be:

• composition of a specific dosage form (excipients, coatings)
• formulation claims (granulation, tableting parameters, particle size distributions)
• manufacturing process claims (milling, drying, crystallization)
• method-of-use claims (uncommon for long-used actives, but can exist for specific subpopulations or dosing guidance)

---

When does antithyroid drug exclusivity expire for antithyroid agents like methimazole and PTU?

Short answer: For methimazole and PTU, exclusivity and compound patent expirations are historically long past, and generics generally rely on ANDA availability rather than waiting for brand exclusivity. Any remaining exclusivity would be product-specific and tied to a specific NDA.

Typical exclusivity sources relevant to the MeSH class

If a still-protected antithyroid product exists, it would most commonly be tied to:

• patent term extensions (PTE) for a still-on-patent NDA
• pediatric exclusivity (6-month extensions) if applicable
• orphan exclusivity (unlikely for mainstream hyperthyroidism drugs)
• new chemical entity (NCE), new clinical investigation, or formulation exclusivities (historically less likely for older drugs)

Generic entry practical timeline

For methimazole and PTU standard oral forms:

• generic entry risk is not governed by near-term brand exclusivity
• it is governed by ongoing ANDA market structure, supply chain capacity, and any site-specific manufacturing/IP barriers

---

Which companies control supply and pricing dynamics for methimazole and PTU, and what matters for contracts?

Short answer: Pricing and availability are driven by a concentrated generic manufacturing and distribution footprint, with contract pricing and temporary supply constraints playing outsized roles versus patent exclusivity.

Market dynamics that move prices in antithyroid agents

• Drug shortages and distribution: temporary capacity losses by a few manufacturers can tighten supply and lift prices quickly, even for off-patent actives.
• Multiple generic players: when supply is adequate, competitive generic pricing compresses margins.
• Formulation uniformity and stability: solid oral dosage requirements cause manufacturing bottlenecks to translate directly into market availability.
• Therapeutic switching inertia: physicians may be cautious when a patient changes brand or generic unless stability is proven and tolerability is consistent.

What payers and pharmacy benefit managers optimize

• net price under contracts (rebates)
• acquisition cost during shortage windows
• formulary placement and substitution rules
• monitoring requirements for safety labels (especially PTU liver risk)

---

What generic entry risks exist for antithyroid agents via Paragraph IV certifications?

Short answer: Paragraph IV risk is generally low for methimazole and PTU because the brand active-ingredient patent estate is widely expired. Where Paragraph IV is used, it typically targets any still-listed Orange Book patents on a specific product with remaining formulation, process, or method-of-use claims.

How Paragraph IV plays out in practice for off-patent antithyroid actives

• If no Orange Book-listed patents remain for a reference-listed drug (RLD), ANDA applicants generally certify non-infringement or no patent and proceed without Paragraph IV.
• If formulation/process patents are still listed, Paragraph IV can occur, but the claim scope usually focuses on specific manufacturing parameters rather than the molecule itself.

What litigation tends to look like

• short, product-scoped disputes centered on formulation or process
• settlement-driven resolution where branded supply agreements or manufacturing carveouts are used to avoid prolonged injunction battles

---

What is the Orange Book status of methimazole and propylthiouracil antithyroid products?

Short answer: The Orange Book is populated with many generic listings for methimazole and PTU across strengths and dosage forms, and active-ingredient brand exclusivities have generally expired. Any current “still protected” status would depend on the specific RLD and dosage form and would be best confirmed per NDC/ANDA pairing.

What to look for in Orange Book entries for MeSH “Antithyroid Agents”

• whether any listed patents are still in force
• whether those patents are formulation/process vs. compound
• whether there is unexpired exclusivity (rare now for these old actives)
• listed drug product (RLD) vs. generic reference

(No product identifiers were provided, so a product-level Orange Book table cannot be produced accurately.)

---

How does patent coverage for antithyroid formulation and manufacturing methods affect ANDA design-around strategies?

Short answer: For generic antithyroid solids, the most plausible IP barriers are manufacturing-process and formulation-excipient system claims, because those can be narrower than compound claims but still cover specific drug-product characteristics.

Common formulation variables that can appear in antithyroid patents

• excipient selection and ratios (binders, disintegrants)
• coating and dissolution modifiers (for any nonstandard release)
• particle size and flow properties impacting uniformity
• granulation and compression parameters

Common process variables

• crystallization or milling specifications
• drying steps and residual solvent/water limits
• blending order and mixing validation ranges
• sterilization is generally not relevant for oral tablets/capsules, but drying and moisture control are

---

Do antithyroid agents have biologic or biosimilar competition that changes patent strategy?

Short answer: No. Methimazole and PTU are small-molecule drugs, not biologics. Biosimilar pathways and BLA patent estates do not apply.

---

What patent litigation affects the antithyroid agents market for methimazole and PTU?

Short answer: Litigation exists in generic markets for many drugs, but for antithyroid actives, barriers are usually not sustained because patents are largely expired and product-level disputes resolve quickly or fail to block approval at scale.

What tends to be litigated

• infringement of formulation/process patents tied to a specific RLD
• dispute scope around dissolution profiles or manufacturing conditions

(A specific litigation map requires product-level RLD and Orange Book identifiers.)

---

How do regulatory pathways influence patent and market outcomes for antithyroid agents?

Short answer: Generic antithyroid entries are almost always ANDA-based and driven by bioequivalence and quality systems rather than patent-driven clinical trial exemptions.

FDA pathway implications

• ANDA: requires bioequivalence for solid oral generics, which often accelerates entry once any patents/exclusivities clear.
• RLD identification: determines whether any still-listed patents require Paragraph IV challenges.
• Quality and stability: can affect launch timing even in a fully off-patent landscape.

---

How does market competition differ between methimazole and propylthiouracil under patent expiration and supply shocks?

Short answer: Both are off-patent in major markets, but practical demand patterns and safety label usage can shift competitive dynamics. PTU often faces more constrained prescribing in many settings because of hepatotoxicity concerns, while methimazole typically has broader routine use.

Commercial exposure channels

• demand volume and prescriber behavior
• acquisition cost volatility during shortages
• contracting stability and switching policies

---

Key Takeaways

• Patent-driven exclusivity is not the main market driver for most antithyroid agents in MeSH Class; methimazole and PTU are largely off-patent.
• Residual IP, when present, is typically product-specific (formulation/process) and tends to be narrower than compound-level claims.
• Generic entry risk is generally low for standard methimazole and PTU due to expired core patents, with any Paragraph IV risk dependent on still-listed Orange Book patents tied to specific RLDs.
• Supply constraints and contracting determine near-term price moves more than legal exclusivity.
• Biosimilar strategy is not relevant for this MeSH class because the drugs are small-molecule therapies.

---

FAQs

1. Do methimazole and PTU have any FDA 505(b)(1) brand developments still affecting exclusivity in antithyroid therapy?
2. What formulation patents most commonly block generic solid oral drugs when active ingredient patents are expired?
3. How do PTU safety label restrictions affect generic market uptake compared with methimazole?
4. What is the typical Orange Book pattern for long-established small-molecule drugs in the antithyroid category?
5. How do drug shortages translate into pricing and patient access changes for off-patent antithyroid tablets and capsules?

---

References (APA)

1. National Library of Medicine. Medical Subject Headings (MeSH): Antithyroid Agents.
2. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
3. U.S. Food and Drug Administration. Drug shortages and safety alerts program (public communications).